Table 7 Relationship between of TICAM2 expression and clinical characteristics of patients with CESC
Gene | Characteristics | Total (N) | Odds ratio (OR) | P value |
|---|---|---|---|---|
TICAM2 | Age (≤ 50 vs. > 50) | 304 | 0.447 (0.123–1.621) | 0.219 |
BMI (≤ 25 vs. > 25) | 259 | 1.924 (0.440–8.369) | 0.381 | |
Menopause status (Pre vs. Peri and Post) | 231 | 0.590 (0.131–2.619) | 0.488 | |
Histological type (adenosquamous vs. squamous cell carcinoma) | 304 | 0.144 (0.018–0.922) | 0.053 | |
T stage (T1 and T2 vs. T3 and T4) | 241 | 0.074 (0.010–0.536) | 0.009 | |
N stage (N0 vs. N1) | 193 | 0.624 (0.101–4.073) | 0.614 | |
M stage (M0 vs. M1) | 126 | 0.454 (0.012–33.647) | 0.690 | |
Clinical stage (stage I and stage II vs. stage IV and stage III) | 297 | 0.278 (0.063–1.258) | 0.091 | |
Histologic grade (G1 and G2 vs. G4 and G3) | 272 | 3.791 (0.924–16.721) | 0.070 | |
Primary therapy outcome (SD and PR and CR vs. PD) | 217 | 0.083 (0.009–0.783) | 0.025 | |
Radiation therapy (yes vs. no) | 304 | 1.287 (0.356–4.799) | 0.702 |